Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz 24/01/2025 by Yasir Jared Holz, Mizuho, joins ‘Fast Money’ to talk Novo Nordisk’s recent climb. Source link
